167 related articles for article (PubMed ID: 23543268)
1. Bevacizumab in the treatment of ovarian cancer: a meta-analysis from four phase III randomized controlled trials.
Ye Q; Chen HL
Arch Gynecol Obstet; 2013 Sep; 288(3):655-66. PubMed ID: 23543268
[TBL] [Abstract][Full Text] [Related]
2. Angiogenesis Inhibitors for the Treatment of Ovarian Cancer: An Updated Systematic Review and Meta-analysis of Randomized Controlled Trials.
Wang H; Xu T; Zheng L; Li G
Int J Gynecol Cancer; 2018 Jun; 28(5):903-914. PubMed ID: 29561301
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials.
Wu YS; Shui L; Shen D; Chen X
Oncotarget; 2017 Feb; 8(6):10703-10713. PubMed ID: 27793044
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a meta-analysis.
Wang M; Zheng X; Ruan X; Ye B; Cai L; Lin F; Tu J; Jiang F; Li S
Chin Med J (Engl); 2014; 127(3):538-46. PubMed ID: 24451964
[TBL] [Abstract][Full Text] [Related]
5. Phase III trials of standard chemotherapy with or without bevacizumab for ovarian cancer: a meta-analysis.
Zhou M; Yu P; Qu X; Liu Y; Zhang J
PLoS One; 2013; 8(12):e81858. PubMed ID: 24324725
[TBL] [Abstract][Full Text] [Related]
6. Addition of bevacizumab to chemotherapy in patients with ovarian cancer: a systematic review and meta-analysis of randomized trials.
Li J; Zhou L; Chen X; Ba Y
Clin Transl Oncol; 2015 Sep; 17(9):673-83. PubMed ID: 25990506
[TBL] [Abstract][Full Text] [Related]
7. Hypertension as a predictive marker for bevacizumab in metastatic breast cancer: results from a retrospective matched-pair analysis.
Gampenrieder SP; Romeder F; Muß C; Pircher M; Ressler S; Rinnerthaler G; Bartsch R; Sattlberger C; Mlineritsch B; Greil R
Anticancer Res; 2014 Jan; 34(1):227-33. PubMed ID: 24403467
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab and ovarian cancer.
Sato S; Itamochi H
Curr Opin Obstet Gynecol; 2012 Feb; 24(1):8-13. PubMed ID: 22123222
[TBL] [Abstract][Full Text] [Related]
9. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.
Brufsky AM; Hurvitz S; Perez E; Swamy R; Valero V; O'Neill V; Rugo HS
J Clin Oncol; 2011 Nov; 29(32):4286-93. PubMed ID: 21990397
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study.
Kozloff M; Yood MU; Berlin J; Flynn PJ; Kabbinavar FF; Purdie DM; Ashby MA; Dong W; Sugrue MM; Grothey A;
Oncologist; 2009 Sep; 14(9):862-70. PubMed ID: 19726453
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab in the treatment of advanced, non-squamous non-small cell lung cancer: an evidence-based approach.
Tassinari D; Sartori S; Papi M; Drudi F; Castellani C; Carloni F; Tombesi P; Lazzari-Agli L
Oncology; 2011; 80(5-6):350-8. PubMed ID: 21791945
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and toxicity of angiogenesis inhibitors for ovarian cancer: a meta-analysis of randomized controlled trials.
Guo C; Yan C; Qu L; Du R; Lin J
Arch Gynecol Obstet; 2021 Feb; 303(2):285-311. PubMed ID: 33222040
[TBL] [Abstract][Full Text] [Related]
13. A meta-analysis of bevacizumab combined with chemotherapy in the treatment of ovarian cancer.
Wang TS; Lei W; Cui W; Wen P; Guo HF; Ding SG; Yang YP; Xu YQ; Lv SW; Zhu YL
Indian J Cancer; 2014 Mar; 51 Suppl 3():e95-8. PubMed ID: 25818743
[TBL] [Abstract][Full Text] [Related]
14. Prognostic importance of cell-free DNA in chemotherapy resistant ovarian cancer treated with bevacizumab.
Steffensen KD; Madsen CV; Andersen RF; Waldstrøm M; Adimi P; Jakobsen A
Eur J Cancer; 2014 Oct; 50(15):2611-8. PubMed ID: 25087181
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and toxicity of bevacizumab in recurrent ovarian disease: an update meta-analysis on phase III trials.
Marchetti C; De Felice F; Palaia I; Musella A; Di Donato V; Gasparri ML; Musio D; Muzii L; Tombolini V; Panici PB
Oncotarget; 2016 Mar; 7(11):13221-7. PubMed ID: 26657509
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer.
Whyte S; Pandor A; Stevenson M; Rees A
Health Technol Assess; 2010 Oct; 14(Suppl. 2):47-53. PubMed ID: 21047491
[TBL] [Abstract][Full Text] [Related]
17. A clinical experience of single agent bevacizumab in relapsing ovarian cancer.
Emile G; Chauvenet L; Tigaud JM; Chidiac J; Pujade Lauraine E; Alexandre J
Gynecol Oncol; 2013 Jun; 129(3):459-62. PubMed ID: 23474345
[TBL] [Abstract][Full Text] [Related]
18. Safety of bevacizumab in patients with metastatic breast cancer.
Hamilton EP; Blackwell KL
Oncology; 2011; 80(5-6):314-25. PubMed ID: 21778772
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
Shih T; Lindley C
Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
[TBL] [Abstract][Full Text] [Related]
20. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
Schmoll HJ; Cunningham D; Sobrero A; Karapetis CS; Rougier P; Koski SL; Kocakova I; Bondarenko I; Bodoky G; Mainwaring P; Salazar R; Barker P; Mookerjee B; Robertson J; Van Cutsem E
J Clin Oncol; 2012 Oct; 30(29):3588-95. PubMed ID: 22965961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]